• Users Online: 442
  • Print this page
  • Email this page
Year : 2020  |  Volume : 3  |  Issue : 2  |  Page : 264-269

Rivaroxaban: Drug review

1 Department of Medical Oncology, HBCH/MPMMCC, Varanasi, Uttar Pradesh, India
2 Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
3 Department of Surgical Oncology, HBCH/MPMMCC, Varanasi, Uttar Pradesh, India
4 Department of Pharmacy, Amity University, Lucknow, Uttar Pradesh, India
5 Department of Biotechnology, Bangalore University, Bengaluru, Karnataka, India

Correspondence Address:
Abhishek Kumar Singh
Department of Medical Oncology, HBCH/MPMMCC, Varanasi, Uttar Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/CRST.CRST_122_19

Get Permissions

Cancer-associated thrombosis is a challenging problem when treating patients with cancer. It is recurrent and difficult to treat because of the increased risk of bleeding. Low-molecular-weight heparin is the standard of care for treating cancer-associated venous thromboembolism/pulmonary embolism (VTE/PE). Recently, there have been emerging data favoring the use of direct oral anticoagulants (DOACs) for treating cancer-associated VTE/PE. They are well tolerated because of oral administration and favorable side effect profile. Rivaroxaban was the first DOAC to be approved by the US Food and Drug Administration in 2012. In this comprehensive review, we discuss the history, chemistry, mechanism of action, indications, dose modifications, and drug–drug interactions of rivaroxaban. We also discuss briefly the results of various clinical trials related to DOACs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal